Workflow
江苏吴中医药发展股份有限公司关于副总裁、财务总监辞职暨总裁代行财务总监职责的公告

Group 1 - The company announced the resignation of Vice President and Chief Financial Officer Sun Xi due to work adjustments, effective from August 21, 2025 [2] - The board approved the proposal for the company's President Jiang Zhong to temporarily assume the duties of the Chief Financial Officer until a new appointment is made [2] - The company will promptly hire a new Chief Financial Officer and fulfill related disclosure obligations as per legal requirements [2] Group 2 - The company is under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure laws, leading to a risk warning for potential delisting due to major violations [5][6] - The company received a notice from the CSRC on July 13, 2025, indicating that it had inflated revenue, costs, and profits in its annual reports from 2020 to 2023, with inflated revenues amounting to approximately 495.26 million yuan in 2020, 468.51 million yuan in 2021, 430.75 million yuan in 2022, and 376.66 million yuan in 2023 [7] - The company's stock price has been below 1 yuan for six consecutive trading days, which could lead to termination of listing if it remains below this threshold for 20 consecutive trading days [5][6]